Skip to content

The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson's Disease

The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04955275
Enrollment
25
Registered
2021-07-08
Start date
2021-06-01
Completion date
2022-04-01
Last updated
2022-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Purpose/Goal: To determine if a remote computerized cognitive remediation program (CRT) can stabilize or improve cognitive functioning in a group of patients from the New York Institute of Technology Academic Health Care Center with Parkinson's disease (PD) after three months of intervention. Hypothesis: Patients with PD who present with current cognitive deficits will show improvement in such deficits after three months of participation in a remotely supervised structured Cognitive Remediation Therapy Program (CRT) compared to control subjects with PD who receive treatment as usual. Research design: Pilot study. Prospective randomized treatment and control comparison pre-post study.

Interventions

OTHERCognitive Remediation Therapy Program (BrainHQ)

Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.

Sponsors

New York Institute of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Subjects must be currently enrolled in the Rock Steady Boxing Program at the Adele Smithers Parkinson's Disease Center. 2. Subjects must be between 40 and 85 years old (including both ages) at the time of study screening. 3. Subjects must have a diagnosis of Parkinson's disease by a physician. 4. Subjects must have a MOCA score of 20 or above. 5. Subjects must demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in this research study. 6. Subjects must have been clinically stable for 2 weeks prior to consent; in the judgment of the Investigator. 7. Subjects must have the visual, auditory, and motor capacity to use the intervention in the judgment of the Principal Investigator. 8. Subjects must be technologically capable of utilizing a computer and navigating through the programs. 9. Subjects must be mechanically capable of utilizing a computer and computer mouse.

Exclusion criteria

1. Subjects should not be participating in a concurrent research study or other interventional clinical trial 30 days prior to consenting. 2. Subjects should not have a history of mental retardation or pervasive developmental disorder; or other co-morbid neurological disorder (e.g., epilepsy.) 3. Subject is unable to physically use a computer or a computer mouse. 4. Subject is unable to or refuses to give consent.

Design outcomes

Primary

MeasureTime frameDescription
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Pre-InterventionInitially, before any intervention/start of study.A brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory.
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Post-Intervention10 weeks after intervention/completion of the study.A brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory.
Parkinson's Disease Questionnaire (PDQ-39) Pre-InterventionInitially, before any intervention/start of study.A test that assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.
Parkinson's Disease Questionnaire (PDQ-39) Post-Intervention10 weeks after intervention/completion of the study.A test that assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.
Montreal Cognitive Assessment (MOCA) Pre-Intervention ScreeningInitially, before any intervention/start of study.A rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026